The development and use of vaccine adjuvants

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 21, Issue 2, 2002, Pages 129-148

  Edelman, Robert ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Adjuvant mechanisms; Adjuvant safety; Phase I and II clinical trials; Vaccine adjuvants

Indexed keywords

ALPHA INTERFERON; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BCG VACCINE; CALCITRIOL; CALCIUM PHOSPHATE; CARRIER PROTEIN; CORD FACTOR; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; DRUG VEHICLE; ENTEROTOXIN; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; MURABUTIDE; MURAMYL DIPEPTIDE; MURAMYL TRIPEPTIDE; OLIGODEOXYNUCLEOTIDE; PHOSPHORYL LIPID A; POLYACRYLIC ACID; POLYANION; PRASTERONE; UNINDEXED DRUG; VACCINE; VIRUS VECTOR;

CLINICAL TRIAL; DRUG FORMULATION; DRUG SCREENING; DRUG USE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; REVIEW; SIDE EFFECT; VACCINE PRODUCTION; ANIMAL; DISEASE MODEL; IMMUNOASSAY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMAN; IMMUNOASSAY; VACCINES; ANIMALS; HUMANS;

ANIMALIA; MYCOBACTERIUM BOVIS BCG;

EID: 0036090510     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:21:2:129     Document Type: Review

References (149)

1. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidipherique
2. Vaccine adjuvants
3. Adjuvants - A balance between toxicity and adjuvanticity
4. Adjuvants for human vaccines - Current status, problems and future prospects
5. The selective induction of different immune responses by vaccine adjuvants
6. Copolymer adjuvants in malaria vaccine development
7. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases
8. Adjuvants - A classification and review of their modes of action
9. Recent advances in vaccine adjuvants for systemic and mucosal administration
10. Novel adjuvants currently in clinical testing November 2-4,1998, Fondation Merieux, Annecy, France: A meeting sponsored by the World Health Organization
11. Adjuvants designed for veterinary and human vaccines
12. The children's vaccine initiative - Will it work?
13. Introducing GAVI and the Global Fund for Children's Vaccines
14. Procedes pour accroitre la production des antitoxines
15. Adjuvants: Current status, clinical perspectives and future prospects
16. Adjuvants
17. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines
18. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
19. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine
20. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
21. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine
22. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
23. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans
24. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: A candidate Lyme disease Vaccine
25. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
26. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
27. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines
28. The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine
29. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
30. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant
31. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy
32. Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines
33. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine
34. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
35. Influenza vaccination in the elderly: Improved antibody response with Imuthiol (Na diethyldithiocarbamate) adjuvant therapy
36. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study
37. A new approach to vaccine adjuvants: Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine
38. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients
39. A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine
40. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly
41. Optimism over vaccines administered via mucosal surfaces
42. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres
43. A Phase I safety and immunogenicity trial of UBI(R) microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV- 1 seronegative human subjects
44. Proteosomes for improved nasal, oral, or injectable vaccines
45. Safety and immunogenicity of a proteosome-shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults
46. Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers
47. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
48. Lipid matrix-based subunit vaccines: A structure-function approach to oral and parenteral immunization
49. Immuno-potentiating reconstituted influenza virosomes as a novel antigen delivery system
50. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
51. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant
52. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit
53. Perspectives of anti-H, pylori vaccination
54. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit
55. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
56. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine
57. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection
58. Mutants of Escherichia coli heat-labile toxin lacking ADP- ribosyltransferase activity act as nontoxic, mucosal adjuvants
59. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
60. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants
61. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids
62. Reactogenicity and passage into the brains of enterotoxins and cpg-oligonucleotides administered intranasally to mice
63. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system
64. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C
65. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
66. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes
67. Skin immunization made possible by cholera toxin
68. Transcutaneous immunization: A human vaccine delivery strategy using a patch
69. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants
70. Immunology of the skin and the eye
71. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
72. The induction of systemic and mucosal immune responses to antigen- adjuvant compositions administered into the skin: Alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity
73. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
74. Safety and immunogenicity of a transcutaneously administered prototype traveler's diarrhea vaccine consisting of heat-labile toxin (LT) and CS6 colonization factor of enterotoxigenic Escherichia coli (ETEC)
75. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA
76. Immunological and formulation design consideratins for subunit vaccines
77. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses
78. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant
79. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism
80. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response
81. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid
82. Structural and immunological characterization of the vaccine adjuvant QS-21
83. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions
84. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195
85. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies
86. Synthetic peptide vaccine design: Synthesis and properties of a high- density multiple antigenic peptide system
87. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
88. NCVDG working groups: Safety evaluation of vaccine adjuvants: National cooperative vaccine development meeting working group
89. Preclinical safety assessment considerations in vaccine development
90. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382)
91. Making vaccines more acceptable - Methods to prevent and minimize pain and other common adverse events associated with vaccines
92. Effect of DETOX as an adjuvant for melanoma vaccine
93. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant
94. The multi-epitope polypeptide approach in HIV-1 vaccine development
95. Bacille Calmette-Guerin immunization in normal healthy adults
96. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin
97. Antigen-specific recall urticaria to a peptide-based vaccine
98. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States
99. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial
100. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans
101. Uveitis induction in the rabbit by muramyl dipeptides
102. Immunological adjuvants: Desirable properties and side-effects
103. Adjuvant effects on human immune responses in recipients of candidate HIV vaccines
104. Experimental joint disease: Observations on adjuvant-induced arthritis
105. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement
106. Mineral oil adjuvants: Biological and chemical studies
107. Control of influenza and poliomyelitis with killed virus vaccines
108. Adjuvant influenza vaccines
109. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953
110. Long-term follow-up of Army recruits immunized with Freund's incomplete adjuvanted vaccine
111. Adverse events and vaccination the lack of power and predictability of infrequent events in pre-licensure study
112. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
113. Response of infants to pertussis vaccine at one week and to poliomyelitis, diptheria, and tetanus vaccine at six months
114. The present status of field and laboratory studies of typhoid and paratyphoid vaccines with special reference to studies sponsored by the World Health Organization
115. Long-term follow-up of the initial (1959-1960) trachoma vaccine field on Taiwan
116. Antigenicity of alum and aqueous adenovirus hexon antigen vaccines in man
117. Lack of adjuvant effect of AIPO4 on purified influenza virus haemagglutinins in man
118. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 8- to 23-month-old children
119. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles
120. Adjuvant properties of aluminum and calcium compounds
121. Aluminum salts: Prospectives in their use as adjuvants
122. Recommendations for the assessment of adjuvants (immunopotentiators)
123. Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid
124. Comparative efficacy of a whole killed SIV vaccine in combination with various adjuvants
125. Initial clinical evaluation of new vaccine candidates: Phase 1 and 2 clinical trials of safety, immunogenicity, and preliminary efficacy
126. Regulatory considerations in vaccine design
127. Adjuvants for the future
128. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines
129. Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin
130. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: Comparison of adjuvants, doses and challenge viruses
131. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP- PE/MF59
132. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial
133. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
134. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
135. Safe ty and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
136. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria
137. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania
138. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A
139. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers
140. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine
141. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine
142. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
143. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
144. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria